FDA warning on Asthma Drugs

[Guest guest]

I took adivair and my heart raced out of my mouth and then worse asthma attack I ever had!! I will never use it again!

Janet

In a message dated 8/18/03 4:49:14 AM Eastern Daylight Time, astakky@... writes:

Subj:[] FDA warning on Asthma Drugs

Date:8/18/03 4:49:14 AM Eastern Daylight Time

From:astakky@...

Reply-to:

Sent from the Internet

New Warnings Added to Glaxo Asthma Drugs: US FDA

WASHINGTON (Reuters) Aug 14 - GlaxoKline Plc's asthma drugs Serevent and Advair will carry new warnings about a small risk of life-threatening asthma episodes or asthma-related deaths, the Food and Drug Administration said Thursday.

The FDA, in a statement, said the benefits of treating patients with Serevent or Advair continue to outweigh the risks when used according to instructions.

Both drugs contain an active ingredient called salmeterol, a long-acting beta agonist that relaxes the bronchial muscles and allows patients to breath more easily.

Serevent was launched on the U.S. market in 1994. The company began a study of the drug in 1996 to address safety questions.

In January, GlaxoKline announced it halted the Serevent trial after seeing more life-threatening asthma episodes, including deaths, in patients treated with the drug rather than a placebo.

Officials at GlaxoKline were not immediately available for comment.

[Guest guest]

New Warnings Added to Glaxo Asthma Drugs: US FDA

WASHINGTON (Reuters) Aug 14 - GlaxoKline Plc's asthma drugs Serevent and Advair will carry new

warnings about a small risk of life-threatening asthma episodes or

asthma-related deaths, the Food and Drug Administration said Thursday.

The FDA, in a statement, said the benefits of treating patients with

Serevent or Advair continue to outweigh the risks when used according

to instructions.

Both drugs contain an active ingredient called salmeterol, a

long-acting beta agonist that relaxes the bronchial muscles and allows

patients to breath more easily.

Serevent was launched on the U.S. market in 1994. The company began a

study of the drug in 1996 to address safety questions.

In January, GlaxoKline announced it halted the Serevent trial

after seeing more life-threatening asthma episodes, including deaths,

in patients treated with the drug rather than a placebo.

Officials at GlaxoKline were not immediately available for comment.